Qlucore Newsletter: Simplify Bladder Cancer Classification and FGFR fusion gene detection

Approval of erdafitinib for a subgroup of urothelial cancers highlights the importance of both classification and fusion detection in tumors.  However, the analysis and interpretation of the data from an expression profile is far from trivial. In response, Qlucore Insights was developed as a tool to enable easy expression profile-based classification of tumors. 

Webinar: “Precision classification of Bladder tumors with Qlucore Insights” 3rd of October at 11am CET. Book 

Introduction Video: Qlucore Insights | Qlucore 

One of the models available for Qlucore Insights deals with classification of bladder tumors. The bladder cancer sub-type classification in Qlucore Insights is based on a machine learning algorithm of gene expression profiles from reference samples. The program also reports any fusions present in the sample. The importance of fusion detection is underscored by the recent approval of the first pan FGFR kinase inhibitor, erdafitinib, for adults with unresectable or metastatic urothelial carcinoma with FGFR3 alterations. With Qlucore Insights both expression profiling and fusion detection are performed automatically and presented in a report! 

During the webinar we will guide you step-by-step on how to perform this analysis, from raw data to a finalized report. You will learn the benefits of RNA-sequencing based subclassification with gene fusion analysis integrated in the workflow for added predictive power.  

Welcome!